A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
NCT ID: NCT05137067
Last Updated: 2025-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
90 participants
INTERVENTIONAL
2021-01-20
2023-05-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer
NCT00905658
Study of an Experimental New Drug, PPARĪ³ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
NCT00408434
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer
NCT00547547
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC
NCT03130829
Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer
NCT03563352
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chemotherapeutic agent A (Docetaxel)
The patients with breast cancer will receive chemotherapeutic agent A
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Chemotherapeutic agent A (Docetaxel) plus placebo
The patients with breast cancer will receive chemotherapeutic agent A plus a placebo.
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo
Placebo
Chemotherapeutic agent A (Docetaxel) plus RaproCell
The patients with breast cancer will receive chemotherapeutic agent A plus RaproCell.
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)
Chemotherapeutic side effect elimination without adversely effecting the Chemotherapeutic agent drug.
Chemotherapeutic agent B (Cisplatin)
The patients with lung cancer will receive Chemotherapeutic agent B
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Chemotherapeutic agent B (Cisplatin) plus placebo
The patients with lung cancer will receive Chemotherapeutic agent B plus placebo.
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo
Placebo
Chemotherapeutic agent B (Cisplatin) plus RaproCell
The patients with lung cancer will receive Chemotherapeutic agent B plus RaproCell.
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)
Chemotherapeutic side effect elimination without adversely effecting the Chemotherapeutic agent drug.
Chemotherapeutic agent C (Docetaxel)
The patients with prostate cancer will receive Chemotherapeutic agent C
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Chemotherapeutic agent C (Docetaxel) plus placebo
The patients with prostate cancer will receive Chemotherapeutic agent C plus placebo.
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo
Placebo
Chemotherapeutic agent C plus (Docetaxel) RaproCell
The patients with prostate cancer will receive Chemotherapeutic agent C plus RaproCell.
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)
Chemotherapeutic side effect elimination without adversely effecting the Chemotherapeutic agent drug.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)
Chemotherapeutic side effect elimination without adversely effecting the Chemotherapeutic agent drug.
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo
Placebo
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Active lung cancer patients taking one of the studies listed drugs within the age range.
Active prostate cancer patients taking one of the studies listed drugs within the age range.
\-
\-
25 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Optimal Health Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
EA Jeppsen, MD
Role: STUDY_CHAIR
Optimal Health Clinic
Steven Osguthorpe, ND
Role: PRINCIPAL_INVESTIGATOR
Optimal Health Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Optimal Health Research
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RPC006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.